Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253070, C514S307000, C514S339000, C514S378000, C544S060000, C544S128000, C544S363000, C546S175000, C548S240000
Reexamination Certificate
active
07125870
ABSTRACT:
The present application describes novel isoxazoline of formula I or II:or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof.
REFERENCES:
patent: 4769461 (1988-09-01), Musser et al.
patent: 5716967 (1998-02-01), Kleinman
patent: 5869511 (1999-02-01), Cohan et al.
patent: 6114367 (2000-09-01), Cohan et al.
patent: 6211216 (2001-04-01), Willms et al.
Kleinman, E.F. et al., “Striking Effect of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNFα Inhibitory Activity of Two Series of Rolipram Analogues: Implications for a New Active Site Model of PDE4”, J. Med. Chem., vol. 41, pp. 266-270 (1998).
Maduskuie Thomas P.
Mercer Stephen E.
Xue Chu-Biao
Bristol--Myers Squibb Company
Sackey Ebenezer
Shameem Golam M. M.
Sun Jing G.
LandOfFree
Isoxazoline derivatives as inhibitors of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazoline derivatives as inhibitors of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazoline derivatives as inhibitors of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694733